Arecor Therapeutics PLC Arecor Appoints Interim Chief Financial Officer
November 18 2024 - 1:00AM
RNS Regulatory News
RNS Number : 5201M
Arecor Therapeutics PLC
18 November 2024
Arecor Therapeutics plc
("Arecor" or "the Company")
APPOINTMENT OF INTERIM CHIEF FINANCIAL
OFFICER
Cambridge, UK, 18
November 2024: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical group advancing today's therapies to enable
healthier lives, today announces the appointment of David Ellam as
Interim Chief Financial Officer (CFO), effective immediately.
David is an experienced finance professional and
chartered accountant, with over two decades of experience in the
life sciences industry. He has held CFO roles at numerous
healthcare companies including Juvenescence, a life sciences
company developing therapies to modify ageing and increase healthy
human lifespan, Silence Therapeutics, a biotechnology company
harnessing the body's natural mechanism of RNA interference (RNAi)
and, more recently, Sixfold Bioscience, a company focused on RNA
delivery using AI/ML. Early in his career, he qualified as an
accountant at PwC, transitioning to a variety of financial and
internal audit roles at companies including Smith & Nephew.
Sarah Howell, Chief
Executive Officer of Arecor, said: "David is a highly experienced finance
executive whose life sciences knowledge and broad financial
expertise will be highly valuable in supporting the business moving
forward including as we continue to execute our strategic
initiatives to drive shareholder value. It is my pleasure to
welcome him to the Arecor team."
-ENDS-
For more information,
please contact:
|
Arecor Therapeutics
plc
|
www.arecor.com
|
|
Dr Sarah Howell, Chief Executive Officer
|
Tel: +44 (0) 1223 426060
Email: info@arecor.com
|
|
|
|
|
Panmure Liberum
Limited (NOMAD and Joint Broker)
|
|
|
Emma Earl, Freddy Crossley, Mark Rogers (Corporate
Finance)
Rupert Dearden (Corporate Broking)
|
Tel: +44 (0) 20 7886 2500
|
|
WG Partners
LLP (Joint Broker)
|
|
|
Nigel Barnes, Satheesh Nadarajah
David Wilson, Claes Spang
|
Tel: +44 (0)203 705 9321
|
|
|
|
|
ICR
Healthcare
|
|
|
Chris Gardner, David Daley, Lindsey Neville
|
Tel: +44 (0) 20 3709 5700
Email: arecor@consilium-comms.com
|
|
|
|
Notes to
Editors
About
Arecor
Arecor Therapeutics plc is a globally focused
biopharmaceutical company transforming patient care by bringing
innovative medicines to market through the enhancement of existing
therapeutic products. By applying our innovative proprietary
technology platform, Arestat™, we are developing an internal
portfolio of proprietary products in diabetes and other
indications, as well as working with leading pharmaceutical and
biotechnology companies to deliver therapeutic products. The
Arestat™ platform is supported by an extensive patent
portfolio.
For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
BOAFZMMMKNVGDZM
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Nov 2024 to Dec 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Dec 2023 to Dec 2024
